• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Defining Endpoints and Biomarkers in Inflammatory Bowel Disease: Moving the Needle Through Clinical Trial Design.

作者信息

Abreu Maria T, Sandborn William J

机构信息

Division of Gastroenterology, University of Miami Miller School of Medicine, Miami, Florida.

Division of Gastroenterology, University of California San Diego, La Jolla, California.

出版信息

Gastroenterology. 2020 Dec;159(6):2013-2018.e7. doi: 10.1053/j.gastro.2020.07.064. Epub 2020 Sep 19.

DOI:10.1053/j.gastro.2020.07.064
PMID:32961246
Abstract
摘要

相似文献

1
Defining Endpoints and Biomarkers in Inflammatory Bowel Disease: Moving the Needle Through Clinical Trial Design.定义炎症性肠病的终点和生物标志物：通过临床试验设计推动进展。
Gastroenterology. 2020 Dec;159(6):2013-2018.e7. doi: 10.1053/j.gastro.2020.07.064. Epub 2020 Sep 19.
2
How Failure Can Fuel Improvements in Early Drug Development for Inflammatory Bowel Diseases.失败如何推动炎症性肠病早期药物研发的改进
Gastroenterology. 2016 May;150(5):1061-1066. doi: 10.1053/j.gastro.2016.03.011. Epub 2016 Mar 24.
3
Non-Invasive Assessment of Inflammation and Treatment Response in Patients with Crohn's Disease and Ulcerative Colitis using Contrast-Enhanced Ultrasonography Quantification.使用对比增强超声量化技术评估克罗恩病和溃疡性结肠炎患者的炎症和治疗反应。
J Gastrointestin Liver Dis. 2015 Dec;24(4):457-65. doi: 10.15403/jgld.2014.1121.244.chr.
4
Methotrexate for inflammatory bowel disease: time for reconsideration.甲氨蝶呤用于炎症性肠病：是时候重新考虑了。
Expert Rev Gastroenterol Hepatol. 2019 May;13(5):407-409. doi: 10.1080/17474124.2019.1596797. Epub 2019 Mar 21.
5
New diagnostic imaging tools for inflammatory bowel disease.用于炎症性肠病的新型诊断成像工具。
Gut. 2006 May;55(5):733-41. doi: 10.1136/gut.2005.076612.
6
Review article: The pharmacokinetics and pharmacodynamics of drugs used in inflammatory bowel disease treatment.综述文章：用于治疗炎症性肠病的药物的药代动力学和药效学
Eur J Clin Pharmacol. 2015 Jul;71(7):773-99. doi: 10.1007/s00228-015-1862-7. Epub 2015 May 27.
7
Expediting Drug Development for Pediatric Inflammatory Bowel Disease: A Workshop to Identify Barriers and Move Forward.加速儿童炎症性肠病药物研发：识别障碍与推进的研讨会
Gastroenterology. 2022 Jan;162(1):22-25. doi: 10.1053/j.gastro.2019.06.022. Epub 2019 Jun 21.
8
Accuracy of Rapid Fecal Calprotectin Test in Monitoring Inflammatory Bowel Diseases Under Treatment with TNFα Antagonists.快速粪便钙卫蛋白检测在监测接受TNFα拮抗剂治疗的炎症性肠病中的准确性。
Dig Dis Sci. 2015 May;60(5):1406-13. doi: 10.1007/s10620-014-3459-x. Epub 2014 Dec 2.
9
Treatment of experimental ulcerative colitis.实验性溃疡性结肠炎的治疗
Bull Exp Biol Med. 2012 Oct;153(6):889-92. doi: 10.1007/s10517-012-1852-z.
10
[FAQs in chronic inflammatory bowel diseases. This way your patient stays in remission].[炎症性肠病常见问题解答。让您的患者维持缓解状态的方法]
MMW Fortschr Med. 2011 Dec 8;153(49-50):20-1. doi: 10.1007/BF03369192.

引用本文的文献

1
Assessment of outcomes in Crohn's disease: A systematic review of randomized clinical trials to inform a multiple outcome framework.评估克罗恩病的结局：一项系统评价随机临床试验，为多结局框架提供信息。
United European Gastroenterol J. 2024 Nov;12(9):1280-1291. doi: 10.1002/ueg2.12679. Epub 2024 Oct 11.
2
Real-world experience with biosimilar infliximab-adba and infliximab-dyyb among infliximab-naïve patients with inflammatory bowel disease in the Veterans Health Administration.在退伍军人事务部的炎症性肠病初治患者中，使用英夫利昔单抗类似药 adba 和 dyyb 的真实世界经验。
Medicine (Baltimore). 2024 Sep 13;103(37):e39476. doi: 10.1097/MD.0000000000039476.
3
Short term effectiveness of ustekinumab versus vedolizumab in Crohn's disease after failure of anti-TNF agents: An observational comparative study design with a Bayesian analysis.
英夫利昔单抗和维得利珠单抗治疗抗 TNF 治疗失败后克罗恩病的短期疗效：一项基于贝叶斯分析的观察性比较研究设计。
Saudi J Gastroenterol. 2024 Sep 1;30(5):324-334. doi: 10.4103/sjg.sjg_101_24. Epub 2024 Aug 19.
4
Add-on multiple submucosal injections of the RNA oligonucleotide GUT-1 to anti-TNF antibody treatment in patients with moderate-to-severe ulcerative colitis: an open-label, proof-of concept study.在中重度溃疡性结肠炎患者中，在抗TNF抗体治疗基础上追加RNA寡核苷酸GUT-1进行多次黏膜下注射：一项开放标签的概念验证研究。
Inflamm Regen. 2024 Apr 25;44(1):22. doi: 10.1186/s41232-024-00332-7.
5
Management of infliximab refractory immune checkpoint inhibitor gastrointestinal toxicity: a multicenter case series.英夫利昔单抗难治性免疫检查点抑制剂胃肠道毒性的管理：一项多中心病例系列研究。
J Immunother Cancer. 2024 Jan 31;12(1):e008232. doi: 10.1136/jitc-2023-008232.
6
The Disease Severity Index for Inflammatory Bowel Disease Is a Valid Instrument that Predicts Complicated Disease.炎症性肠病疾病严重程度指数是一种有效的预测复杂疾病的工具。
Inflamm Bowel Dis. 2024 Nov 4;30(11):2064-2075. doi: 10.1093/ibd/izad294.
7
Risankizumab Induction Therapy Achieves Early Symptom Improvements That Are Associated With Future Clinical and Endoscopic Outcomes in Crohn's Disease: Post Hoc Analysis of the ADVANCE, MOTIVATE, and FORTIFY Phase 3 Studies.里萨尼珠单抗诱导治疗可早期改善症状，与克罗恩病的未来临床和内镜结局相关： ADVANCE、MOTIVATE 和 FORTIFY 三项 3 期研究的事后分析。
J Crohns Colitis. 2024 Jun 3;18(6):818-827. doi: 10.1093/ecco-jcc/jjad206.
8
Filgotinib Improved Health-Related Quality of Life and Led to Comprehensive Disease Control in Individuals with Ulcerative Colitis: Data from the SELECTION Trial.Filgotinib 改善了溃疡性结肠炎患者的健康相关生活质量，并实现了全面的疾病控制：SELECTION 试验的数据。
J Crohns Colitis. 2023 Jun 16;17(6):863-875. doi: 10.1093/ecco-jcc/jjad018.
9
Ozanimod as a novel oral small molecule therapy for the treatment of Crohn's disease: The YELLOWSTONE clinical trial program.奥扎莫德作为一种新型口服小分子治疗药物用于治疗克罗恩病：YELLOWSTONE 临床试验项目。
Contemp Clin Trials. 2022 Nov;122:106958. doi: 10.1016/j.cct.2022.106958. Epub 2022 Oct 5.
10
Validating the Simplified Endoscopic Mucosal Assessment for Crohn's Disease: A Novel Method for Assessing Disease Activity.验证简化内镜黏膜评估克罗恩病：一种评估疾病活动度的新方法。
Inflamm Bowel Dis. 2023 Jul 5;29(7):1089-1097. doi: 10.1093/ibd/izac183.